Brind.

Edwards Lifesciences reported mid-single digit TAVR sales growth and market share rebalancing in Europe.

1 report, 1 independent Updated Jul 25

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Edwards Lifesciences Europe

Keep exploring

The entities involved

Edwards Lifesciences
American medical technology company
- Edwards Lifesciences and InspireMD were compared in a market analysis.Sat 11:51
Europe
terrestrial continent located in north-western Eurasia
- The European Commission aims to strengthen homegrown AI capabilities while global advanced models face usage restrictions.Mon 17:49
- The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49

Related events

FDA approved expanded use of Sapien 3 valves, while Edwards conducts Progress trials and seeks expanded Medicare coverage for TAVR.Sep 21

Coverage

Newest first; wire copies grouped

Jul 25ZacksEW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down Edwards Lifesciences Corporation EW reported second-quarter 2025 adjusted earnings per share (EPS) of 67 cents, which surpassed the Zacks C